文献速递心律失常血脂与心血管预防

标准剂量NOAC与华法林在单卒中风险房颤患者中的有效性和安全性

Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
PubMed 文献 · JAMA Cardiol · 2017-01-01

结果显示NOAC与华法林在缺血性卒中/系统性栓塞风险上无显著差异,但阿哌沙班和达比加群的大出血风险显著低于华法林;因残余混杂,无法对NOAC的相对有效性或安全性做出 definitive 结论。

要点

  • 单卒中风险房颤患者中,NOAC与华法林的缺血性卒中/系统性栓塞风险无显著差异。
  • 阿哌沙班和达比加群的大出血风险显著低于华法林。
  • 因残余混杂,NOAC的相对有效性或安全性无法定论。

核心结论

  • 在仅有1个低危非性别相关卒中风险因素的房颤患者中,标准剂量NOAC与华法林在缺血性卒中/系统性栓塞风险上无显著差异。
  • 阿哌沙班和达比加群的大出血风险显著低于华法林。
  • 由于可能存在残余混杂,无法对NOAC的相对有效性或安全性做出 definitive 结论。

研究设计与样本

  • 全国性观察性队列研究,使用丹麦登记数据,采用逆概率治疗加权比较标准剂量NOAC与华法林的有效性和安全性。

主要发现

  • 主要有效性终点缺血性卒中/系统性栓塞:NOAC与华法林在各层间无显著差异。
  • 任何出血终点:阿哌沙班组风险显著低于华法林组(HR 0.35;95% CI 0.17-0.72),达比加群组也显著低于华法林组(HR 0.48;95% CI 0.30-0.77)。
  • 利伐沙班组任何出血风险与华法林组无显著差异(HR 0.84;95% CI 0.49-1.44)。

关键数值与推荐

  • 标准剂量NOAC定义:达比加群150 mg每日两次,利伐沙班20 mg每日一次,阿哌沙班5 mg每日两次。
  • 任何出血:阿哌沙班 vs 华法林 HR 0.35(95% CI 0.17-0.72);达比加群 vs 华法林 HR 0.48(95% CI 0.30-0.77);利伐沙班 vs 华法林 HR 0.84(95% CI 0.49-1.44)。

临床怎么用

  • 对于仅有1个低危非性别相关卒中风险因素的房颤患者,NOAC与华法林在缺血性卒中/系统性栓塞预防上效果相当。
  • 选择阿哌沙班或达比加群可能降低出血风险,但需考虑观察性研究的残余混杂。

局限性

  • 观察性设计可能存在残余混杂,虚假终点分析未均被证伪,提示选择性处方和未观测协变量的影响。
  • 数据不允许对NOAC的相对有效性或安全性做出 definitive 结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The randomized clinical trials comparing nonvitamin K antagonist oral anticoagulants (NOACs) vs warfarin largely focused on recruiting high-risk patients with atrial fibrillation with more than 2 stroke risk factors, with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk factor. Despite this, regulatory approvals of all NOACs have been based on stroke prevention for patients with atrial fibrillation with 1 or more stroke risk factors. OBJECTIVE: To compare the effectiveness and safety study of standard-dose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) and warfarin in patients with atrial fibrillation with 1 low-risk, nonsex-related stroke risk factor. DESIGN, SETTING, AND PARTICIPANTS: This nationwide observational cohort study used data from Danish registries to determine the inverse probability of treatment-weighted comparative effectiveness and safety of standard-dose NOACs (dabigatran at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) compared with treatment with warfarin among 14 020 patients with atrial fibrillation with 1 low-risk, nonsex- related stroke risk factor. MAIN OUTCOMES AND MEASURES: Rates of ischemic stroke/systemic embolism, death, and bleeding. RESULTS: Of 14 020 participants, 5151 (36.7%) were women, and the median age for participants was 66.5 years. For the principal effectiveness end point of ischemic stroke/systemic embolism, no significant differences of the NOACs compared with treatment with warfarin across strata were evident. For the end point of "any bleeding," this was significantly lower for treatment with apixaban (hazard ratio [HR], 0.35; 95% CI, 0.17-0.72) and dabigatran (HR, 0.48; 95% CI, 0.30-0.77) compared with warfarin in the main analysis, and was not significantly different for treatment with rivaroxaban vs warfarin (HR, 0.84; 95% CI, 0.49-1.44). There was broad consistency across most subgroups in the sensitivity analyses and whether 1- or 2.5-year follow-up periods were analyzed. However, falsification end points generally did not falsify, indicating the possible presence of residual confounding across these comparisons, presumably related to selective prescribing and unobserved covariates. CONCLUSIONS AND RELEVANCE: In this Danish cohort study of patients with atrial fibrillation and a single stroke risk factor, there was no difference between NOACs compared with treatment with warfarin in terms of the risk of having an ischemic stroke/systemic embolism. For "any bleeding," this was lower for treatment with apixaban and dabigatran compared with warfarin. These data do not allow for a definitive statement of the comparative effectiveness or safety of NOACs because of the possible residual confounding that was unmasked with falsification outcomes.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Lip GYH, Skjøth F, Nielsen PB, et al. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. JAMA Cardiol. 2017. PMID: 28614582. doi:10.1001/jamacardio.2017.1883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。